Intranigral iron infusion in rats: A progressive model for excess nigral iron levels in Parkinson’s disease?

  • G. W. Arendash
  • C. W. Olanow
  • G. J. Sengstock
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Increased iron levels are present within the substantia nigra zona compacta (SNc) of Parkinson’s-diseased (PD) brains. Neurodegeneration within the SNc may be a direct consequence of increased iron because of iron’s ability to catalyze cytotoxic free radical formation. We have developed an animal model based on excess nigral iron in PD through intranigral infusion of iron citrate in rats. These infusions cause a long-term and dose-related increase in nigral iron, with accompanying dose-related neuronal loss/gliosis within SNc and associated decreases in striatal dopaminergic markers. Moreover, intranigral iron infusion provides several long-term “progressive” changes including: 1) a progressive decrease in striatal dopamine and HVA, 2) a progressive atrophy of the substantia nigra, and 3) a progressive increase in apomorphine-induced rotational behavior. Since nigral lipid peroxidation is elevated following nigral iron infusion, free radical formation and ensuing oxidative damage may be involved in iron’s neurotoxicity within the substantia nigra. This intranigral iron infusion model could be of extraordinary value in testing antioxidants for treating/preventing PD.


Iron Infusion Iron Staining Iron Citrate Parkinsonian Brain Extensive Neuronal Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Basset P, Quesneau Y, Zwiller J (1986) Iron-induced L1210 cell growth: evidence of a transferrin-independent iron transport. Cancer Res 46: 1644–1647PubMedGoogle Scholar
  2. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J Neurochem 57: 2133–2135PubMedCrossRefGoogle Scholar
  3. Corongiu FP, Dessi MA, Banni S, Bernardi S, Piccardi M, Del Zampo M, Corsini G (1987) MPTP fails to induce lipid peroxidation in vivo. Biochem Pharmacol 36: 2251–2253PubMedCrossRefGoogle Scholar
  4. Dexter DT, Carter CJ, Wells FR, Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989a) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389PubMedCrossRefGoogle Scholar
  5. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989b) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52: 1830–1836PubMedCrossRefGoogle Scholar
  6. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson’s disease. J Neurochem 55: 16–20PubMedCrossRefGoogle Scholar
  7. Good PF, Olanow CW, Perl DP (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson’s disease — a LAMMA study. Brain Res 593: 343–346PubMedCrossRefGoogle Scholar
  8. Halliwell B, Gutteridge JM (1989) Free radicals in biology and medicine, 2nd edn. Oxford University Press, New YorkGoogle Scholar
  9. Hartley A, Cooper JM, Schapira AHV (1993) Iron induced oxidative stress and mitochondrial dysfunction — relevance to Parkinson’s disease. Brain Res (in press)Google Scholar
  10. Irie S, Tavassoli M (1987) Tranferrin-mediated cellular iron uptake. Am J Med Sci 293: 103–111PubMedCrossRefGoogle Scholar
  11. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim, MBH (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm 2: 327–340CrossRefGoogle Scholar
  12. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Youdim MBH (1992) Iron-melanin complex in substantia nigra of Parkinsonian brains: an x-ray microanalysis. J Neurochem 59: 1168–1171PubMedCrossRefGoogle Scholar
  13. Kopin IJ, Schoenberg DG (1988) MPTP in animal models of Parkinson’s disease. Mt Sinai J Med 55: 43–49PubMedGoogle Scholar
  14. Nedergaard M, Goldman SA, Desai S, Pulsinelli WA (1991) Acid-induced death in neurons and glia. J Neurosci 11: 2489–2497PubMedGoogle Scholar
  15. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson’s disease. Ann Neurol 32: S2 - S9PubMedCrossRefGoogle Scholar
  16. Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supra-nuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269–274PubMedCrossRefGoogle Scholar
  17. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds G, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 52: 515–520PubMedCrossRefGoogle Scholar
  18. Sastry S, Arendash GW (1993) Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex (submitted)Google Scholar
  19. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial Complex I deficiency in Parkinson’s disease. J Neurochem 54: 823–827PubMedCrossRefGoogle Scholar
  20. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW (1992) Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 28: 645–649PubMedCrossRefGoogle Scholar
  21. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW (1993a) Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 35: 67–82PubMedCrossRefGoogle Scholar
  22. Sengstock GJ, Dunn AJ, Olanow CW, Barone S, Arendash GW (1993b) Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra (submitted)Google Scholar
  23. Slater TF (1984) Free-radical mechanisms in tissue injury. Biochem J 222: 1–15PubMedGoogle Scholar
  24. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron ( III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205Google Scholar
  25. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978–982PubMedCrossRefGoogle Scholar
  26. Triggs WJ, Willmore LJ (1984) In vivo lipid peroxidation in rat brain following intracortical Fe“ injection. J Neurochem 42: 976–980PubMedCrossRefGoogle Scholar
  27. Willmore LJ, Hiramatsu M, Kochi H, Mori A (1983) Formation of superoxide radicals after FeCI3 injection into rat isocortex. Brain Res 277: 393–396PubMedCrossRefGoogle Scholar
  28. Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 126: 47–54CrossRefGoogle Scholar
  29. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. TINS 13: 290–296PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • G. W. Arendash
    • 1
  • C. W. Olanow
    • 2
  • G. J. Sengstock
    • 1
  1. 1.Department of Biology and Institute for Biomolecular ScienceUniversity of South FloridaTampaUSA
  2. 2.Departments of Neurology, Pharmacology, and PsychiatryUniversity of South FloridaTampaUSA

Personalised recommendations